Objective: To clarify the clinical features of pulmonary cryptococcosis in Japanese non-HIV population. Methods: Retrospective investigation of 151 pulmonary cryptococcosis cases between 1977 and 2012 was executed. The underlying disease (UDs), aggravating factors, radiological characteristics, and treatment were examined.
Introduction
Cryptococcus neoformans is a nonmycelial, budding encapsulated yeast-like fungus found in soil contaminated with pigeon and chicken excreta [1] [2] [3] [4] . Inhalation of cryptococcal particles from contaminated soil into the lung is considered the usual route of human infection [2, 3] . The organism may cause isolated pulmonary infection or hematogenous dissemination involving the central nervous system (CNS), bones, and skin, mostly depending on the host immunity [2, 3] . Although cryptococcal infection can occur in individuals with normal immunity, it most commonly occurs in immunocompromised hosts. Predisposing factors are acquired immune deficiency syndrome (AIDS) and other causes of impaired T cell-mediated immunity, e.g., transplant-related immunosuppression, hematological malignancies, corticosteroid administration, and diabetes mellitus [4] [5] [6] .
Although the clinical characteristics and natural history of cryptococcosis in HIV patients have been described elsewhere due to its large number, those in non-HIV patients have rarely been reported [7] . To date, few studies have reported comparative data regarding the clinical manifestations, laboratory findings, radiographic findings and survival of patients with pulmonary cryptococcosis in Japan [8] . Additionally, very few research comparing clinical manifestation of cryptococcosis between HIV and non-HIV patients [9] [10] [11] .
In Japan, the number of HIV/AIDS patients is relatively lower compared to those of other countries. However, it is increasing recently and over 20,000 of the cumulative patients are registered in Japanese government database to date (http://www.nih.go.jp/niid/ja/aids-m/aids-iasrd/2274-kj3888.html). Hence, the study of clinical manifestation of cryptococcal diseases in non-HIV background possess high impact. We reviewed 151 cryptococcal cases among non-HIV background and investigated the clinical features, including clinical manifestations, underlying conditions, laboratory findings, radiological features, treatment, survival, and outcomes.
Materials and methods

Patients
A retrospective cohort study was conducted by reviewing the medical records of patients who had been diagnosed with pulmonary cryptococcosis at Nagasaki University Hospital and its affiliated hospitals during the 35-year period between 1977 and 2012. The patients were grouped into 2 populations based on positivity of underlying diseases. Definite case of pulmonary cryptococcosis requires isolation or detection of Cryptococcus by lung specimen culture and/or by histopathological examination, and only definite cases are recruited in this study. This retrospective study including analysis and release of clinical data was approved by the ethical committee of Nagasaki University Hospital.
Clinical data
All available patient records were reviewed from the time of cryptococcal diagnosis until the patients died or were lost to follow up.
The data included clinical manifestations, underlying conditions, laboratory findings (age, lymphocyte count, neutrophil count, immunoglobulin, serum protein, serum albumin, CD4/8 ratio, CD4 count, C-reactive protein [CRP], cryptococcal serum antigen titers) at the timing of diagnosis, radiological findings, treatment, survival, and outcome were recorded.
Eiken Latex® (Eiken Kagaku Co., Tokyo, Japan) was used for the qualitative and semi-quantitative detection of the C. neoformans capsular polysaccharide antigen in serum and CSF according to the manufacturer's instructions.
Interpretation of chest CT scans
The findings of chest CT scans were assessed for 1) the presence and distribution of parenchymal lesions, including nodules, masses, and consolidation; 2) the characteristics of nodules and masses; and 3) related thoracic abnormalities such as pleural effusion and lymphadenopathy according to previous reports [12] . Based on the predominant parenchymal findings from the CT scans, the morphological characteristics were classified as solitary nodule/mass (type I), multiple nodules/masses (type II), and consolidation (type III). In addition, type II was subdivided into distribution in a single lobe (type IIa) and distribution in multiple lobes (type IIb).
Statistical analysis
We used FREQ, NPAR1WAY, and ANOVA in SAS. The chi-square test was used to compare the frequency of categorical variables (e.g., underlying disease, steroid usage).
Wilcoxon's test was used to compare age, lymphocyte count, neutrophil count, serum protein, serum albumin, CD4/8 ratio, CD4 count, CRP, and cryptococcal serum antigen titers. The Eiken Latex® latex agglutination test was used to detect cryptococcal polysaccharide. Antigen titers were transformed to the logarithm to the base 2 (Log2[Ag + 1]). Ag (cryptococcal antigen titer) is expressed as 0, 1, 2, 4, … as powers of 2 and Ag + 1 was expressed as Log2(0 + 1) = 0.
For radiographic analysis, a chi-square test was employed to compare the presence and distribution of parenchymal lesions, nodule and mass characteristics except their number, and related thoracic abnormalities between the 2 groups. A Cochran-Armitage test was used to analyze the differences among 4 groups based on the number of nodules and masses, and among 4 morphological types based on the CT classification between the 2 patient populations. For all statistical tests, p < 0.05 indicated a significant difference.
Results
Patients
One hundred fifty-one patients were diagnosed with pulmonary cryptococcosis during the 35-year period between 1977 and 2012. Sixty-seven (44.4%) occurred in the patients without underlying diseases. Forty-two were men and 25 were women.
Eighty-four cases (56.6%) were the patients with underlying disease. Thirty-eight were men and 46 were women.
Underlying diseases
Among 84 patients with underlying diseases, diabetes mellitus was most dominant (32.1%) followed by hematological diseases including human T-cell leukemia virus type-I carrier (22.6%), collagen disease including systemic lupus erythematosus, rheumatoid arthritis and others (22.6%), renal failure (16.7%), solid tumor (13.1%), chronic lung diseases including bronchiectasis, sequel pulmonary tuberculosis, and interstitial pneumonia (13.1%), liver disease including cirrhosis or hepatitis (9.5%), renal transplantation (2.4%) , and other diseases (9.5%). Treatment with glucocorticoids (5-40 mg/day or pulse therapy) were recorded in 31 (37.0%) patients. Total of 5 patients were administrated glucocorticoids concomitantly with immunosuppressant such as cyclosporine and azathioprine.
Clinical symptoms
In 67 patients without underlying diseases, 43 (64.2%) patients were asymptomatic and detected accidentally by mass screening examination. Others had pulmonary symptoms such as cough (n=15; 22.3%), sputum (n=4; 6.0%), chest pain (n=7; 10.4%), fever (n=2; 3.0%), and others. In 84 patients with underlying disease, 39 patients (46.4%) were asymptomatic and found by abnormal chest radiograph findings taken as during routine examination of underlying diseases. Others had pulmonary symptoms such as cough (n=15; 17.6%), sputum (n=15; 17.6%), chest pain (n=3; 3.6%), fever (n=20; 23.8%), and other symptoms (n=19; 22.6%).
Laboratory findings
The laboratory findings of the patients with and without underlying disease at the timing of diagnosis are shown in Table 1 . The patients without underlying disease are statistically younger, better nutrition status reflected by higher total protein and albumin value, compared to those with underlying diseases. Serum antigen titers (Log2[Antigen titer+1]) were not different statistically in both arms.
Compared to steroid non-usage patients (n = 114), steroid usage patients (n= 36) were statistically significantly older (p < 0.0001), had lower lymphocyte count (p = 0.03), higher neutrophil count (p =0.02), lower blood serum protein (p = 0.0002), lower blood serum albumin (p < 0.0001), and higher CRP (p = 0.001). There was no significant difference in IgG, IgA, or IgM between the two groups. Table 2 shows the detail of CT findings between patients with or without underlying diseases. The CT findings of 81 of 151 pulmonary cryptococcosis patients were analyzed. Forty-two and 39 patients were without and with underlying diseases, respectively. The frequency of the four CT classification types based on predominant parenchymal findings and lobar distribution of the lesions is listed in Table 2 . Type IIb and type III lesions occurred more frequently in patients with underlying diseases than in those without underlying diseases. The main finding of this study is the presence of peripherally distributed multiple pulmonary nodules or masses with predominant lower lobe involvement in both patients without and with underlying diseases (P<0.0001, Data not shown). Parenchymal lesions in the right middle lobe (P=0.01), masses and more extensive lung involvement such as multiple lobes in distribution (P=0.06) were more common in patients with underlying disease than those without underlying diseases. The number of masses (>30-mm diameter) (P=0.02) and air bronchogram (P=0.05) was significantly more common in patients with underlying diseases than those without underlying diseases.
CT findings
Serum cryptococcal antigen titer and radiological findings
The relationship of serum cryptococcal antigen titer and radiological findings were analyzed. Data from patients with meningoencephalitis was excluded. For patients with solitary nodules (N = 14), multiple nodules (N = 34) or consolidation (N = 8), comparison of the cryptococcal antigen titer (Log2[Antigen titer + 1]) revealed no significant correlation between solitary and multiple nodules (N.S.); however, a significant higher cryptococcal antigen titer was observed in consolidation when compared with solitary nodules (p <0.01) and multiple nodules (p <0.05) ( Figure 1 ).
Antifungal treatment
The mainstay of initial treatment in both groups was azoles. Fifty-six (83.6%) patients without underlying diseases were initially treated with azoles, fluconazole (including Antifungal agents were administered for 6 months in all patients except three with refractory cryptococcosis among population with underlying diseases.
Transitional serum Cryptococcal antigen titer before and after treatment
Forty definite cases (14 cases with underlying diseases and 26 cases were without underlying disease) which were followed until the serum cryptococcal antigen became negative or up to 45 months after treatment.
Titer changes in the latex agglutination test before and after therapy in patients without underlying disease and with underlying disease are depicted in Figure 2 The mean duration of treatment for 26 patients with underlying diseases was 6.64 months. In the 22 cases where antigen titers became negative after treatment, the mean period from treatment cessation to negative antigen observation was 13.1 months ( Figure 3 ). No significant difference was observed between two groups. The serum antigen titers were decreased after antifungals were discontinued.
Comorbid cryptococcal meningoencephalitis
In 151 of pulmonary cryptococcosis cases, 122 patients were performed lumbar puncture test. Fourteen patients (9.3%) presented CNS involvement. Four and 10 patients were without and with underlying disease, respectively ( Table 3 . Solitary or multiple nodules, consolidation, reticular shadow, granular shadow or mixed findings were observed in meningoencephalitis patients. Pulmonary shadows were seen in both lungs in 7 patients. In meningoencephalitis patients, all patients without underlying disease were improved; however, 6 of 10 patients with underlying disease died. One patient did not have underlying disease; the other had a previous history of diabetes. (Table. 4 ).
Pulmonary cryptococcosis patients who died
Laboratory data correlated to meningoencephalitis and outcome.
The clinical features including laboratory data in the patients with and without cryptococcal meningoencephalitis, and outcome are compared in Table 5 .
Older age, lower lymphocyte counts, higher neutrophil counts, lower serum total protein, lower serum albumin, low CD4/8 ratio, high CRP and higher cryptococcal antigen titer are related to comorbidity of meningoencephalitis. For prognosis, older age, higher neutrophil counts, lower serum total protein, lower serum albumin, and higher CRP are correlated to death. Comorbidity of meningoencephalitis and poor outcome shares same factors.
Discussion
In Japan, the majority of cryptococcosis is seen in non-HIV patients. In the present study, we reviewed the clinical features of 151 pulmonary cryptococcosis in non-HIV patients in Nagasaki, Japan.
Roughly half of the cryptococcosis patients did not have underlying diseases and almost half of patients (82/151, 54.3%) without respiratory symptoms were found accidentally by mass screening examination or routine chest X-ray check. In Japan, there is a unique medical insurance system which allowed people easy and cheap access to medical examination or annual medical check. This background may cause the potential bias in this study.
It is generally recommended that HIV-negative patients with cryptococcal pneumonia undergo routine lumbar puncture to attempt to identify asymptomatic or subclinical CNS involvement that may require more potent or aggressive therapy [13] . However, 2010 updated IDSA guidelines commented as follows, "In nonimmunocompromised patients with pulmonary cryptococcosis, consider a lumbar puncture to rule out asymptomatic CNS involvement. However, for normal hosts with asymptomatic pulmonary nodule or infiltrate, no CNS symptoms, and negative or very low serum cryptococcal antigen, a lumbar puncture can be avoided (B-II)" [14] . Of the 14 patients with cryptococcal meningoencephalitis in this study, 4 did not have underlying disease.
Six patients with meningoencephalitis were dead (eight were survived) and the correlation between comorbidity of meningoencephalitis and poor outcome shares same clinical factors. However, the possibility of existence of meningoencephalitis links significant poor prognosis was not evaluated due to the low number of cases. Of those, 1 patient had solitary nodules, 1× negativity for cryptococcosis antigens, and no CNS disorders. We believe that the necessity of CSF examinations should be debated thoroughly. There has been ongoing discussion regarding the need for lumbar punctures in patients without CNS symptoms. The 2007 Guidelines [15] also recommend lumbar puncture to identify asymptomatic CNS involvement.
To our knowledge, this review of pulmonary cryptococcosis constitutes the largest report to date describing and comparing chest CT findings in non-HIV patients both with and without underlying diseases. Additionally, since many cases were diagnosed from mass screening check-up, it is important to investigate the unique features of radiological findings. Similar to recent studies of immunocompetent hosts [16] [17] [18] [19] and non-AIDS individuals [20] [21] [22] , the most common CT feature was the presence of peripherally distributed multiple pulmonary nodules or masses with predominant lower lobe involvement in both patients without and with underlying diseases Although the number of nodules or masses in previous reports has varied, there was no significant difference in the frequency between multiple nodules or masses (type II) and single lesions (type I) in our series. Multiple nodules or masses distributed in multiple lobes (type IIb) also tended to occur more frequently in patients with underlying diseases than in patients without underlying diseases.
Cryptococcal antigen is widely recognized to have both diagnostic and prognostic value for cryptococcosis. Lu et al. reported on the CSF titer change in the latex agglutination test before and after therapy in non-HIV cryptococcal meningitis. The cryptococcal antigen titer in CSF decreased after therapy for every case and correlated with fungal clearance; however, cryptococcal antigen can remain at low titers for long periods after therapy, even when fungal smear and/or culture become negative. Previous 26 study suggested that the cryptococcal antigen test may not be used as an index of cure [23] .
In this study, serum cryptococcal antigen in pulmonary cryptococcosis patients can remain at low titers for long periods after therapy. However, the titers continuously decrease after effective therapy. Our data demonstrate that the cryptococcal antigens in pulmonary cryptococcosis remain detectable even months following successful therapy, suggesting that the cryptococcal antigen test may not be used as an index of cure or decision of discontinuation of treatment.
The first line antifungal drugs were selected because the facilities that reported these cases were conducting clinical trials for antifungal drug development. Moreover, because the guidelines for cryptococcosis management had not yet been presented before 2007, azole-type drugs + 5-FC were used as pulmonary cryptococcosis treatment for a certain period even in patients without meningoencephalitis.
After the 2007 Guidelines [15] was published, treatment was conducted according to these guidelines' recommendations.
The IDSA guideline for pulmonary cryptococcosis in non-HIV, nonimmunosuppressed patients states that for mild-to-moderate symptoms, fluconazole (400 mg/day orally) should be administered for 6-12 months; persistently positive serum cryptococcal antigen titers are not criteria for continuance of therapy (B-II) [14] .
Conversely, the 2007 Guidelines recommend administering 400 mg/day oral fluconazole for 3 months for immunocompetent pulmonary cryptococcosis patients, and for 6 months for patients with underlying disease [15] .
In our experience, with the exception of some severe cases, the duration of treatments as recommended in the 2007 Guidelines [15] appears appropriate.
In the management of pulmonary cryptococcosis in non-HIV patients, it is important to confirm the presence of underlying disease and encephalomeningitis complications, and a careful treatment plan for patients with severe underlying diseases. IQR : Inter Quartile Range, CRP, C-reactive protein. 
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